BRISTOL MYERS SQUIBB

Bristol Myers Squibb's Opdivo Qvantig, a subcutaneous injection combining nivolumab and hyaluronidase-nvhy, received FDA approval for treating adult solid tumors. Approved based on the CheckMate-67T trial, it offers a quicker, 3-5 minute administration compared to the 30-minute IV Opdivo, marking it as the first subcutaneously administered PD-1 inhibitor.

The FDA approved Bristol Myers Squibb's injectable Opdivo, a PD-1 inhibitor cancer immunotherapy, enhancing patient access and market position as it nears a patent cliff. The new formulation offers faster administration, aiming to maintain sales and market dominance amidst competition.

Corxel Pharmaceuticals acquired VCT220, a Phase 2-ready oral GLP-1 agonist for obesity and diabetes, from Vincentage Pharma, excluding Greater China. Renamed CX11, it aims to offer a patient-friendly alternative to injectable GLP-1 drugs, with Phase 3 trials underway in China and global Phase 2 trials planned for 2025.

The global nephroblastoma treatment market is projected to grow from US$ 1,578.4 million in 2023 to US$ 3,342.8 million by 2033, at a CAGR of 7.8%. North America led with a 43.8% share in 2023. Growth is driven by increasing incidence, advancements in treatment, and new drug developments, though high costs and limited awareness in developing regions pose challenges.

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.

In 2024, South Korean biotech ventures faced challenges with limited investor interest, yet achieved milestones through licensing deals. Notable deals included Nex-I's NXI-101 with Ono Pharmaceutical, Genome & Company's GENA-111 with Debiopharm, Orum Therapeutics' TPD2 platform with Vertex Pharmaceuticals, LigaChem Bio's LCB97 with Ono Pharmaceutical, and Cureverse's CV-01 with Angelini Pharma, showcasing innovation and strategic partnerships in drug development.

2024's medical innovations include gene therapy restoring hearing in deaf children, the first genetically edited pig kidney transplant, a potential lupus cure targeting T-cell imbalance, FDA approval of a new schizophrenia treatment, and a combined COVID-19/flu test with rapid results.

DelveInsight's 2024 report highlights over 50 companies developing 50+ therapies for Systemic Sclerosis, detailing drug profiles, clinical trials, and mechanisms of action. Key players include Eicos Sciences and Corbus Pharmaceuticals, with promising therapies like GS-248 and Lenabasum in development.

Jax DiEugenio hosts *OncLive On Air*, discussing oncology advancements with Dr. Jorge Cortes on luspatercept-aamt's role in treating lower-risk MDS, its benefits over ESAs, and the need for transformative therapies. The podcast, supported by Bristol Myers Squibb, offers insights into improving patient care in oncology.